MannKind (MNKD) & Sanofi (SNY) Are Likely To Climb More Soon!

MannKind Corporation (NASDAQ: MNKD) | Sanofi SA (ADR) (NYSE: SNY)

If you follow my writing here or elsewhere, you know that MannKind stock is one of my favorite topics. The company developed an inhaled insulin called Afrezza that I have high hopes for; and that’s where Sanofi comes in. When it comes to Afrezza, it’s Sanofi’s job to get sales really rolling. While things moved very slow in the pre-launch, a big move is coming that could send MannKind and Sanofi stocks soaring!

A Big Afrezza Campaign Is Just Around The Corner

It has been 5 months since the soft launch of Afrezza by Sanofi, and we haven’t seen any massive sales numbers quite yet. However, that’s likely to change relatively soon. Sanofi is known for its marketing ability when it comes to medications; and within the next “several weeks” the company will be launching a Direct-to-Consumers campaign. Although we’ve heard arguments that Afrezza sales have been incredibly low, it’s important to realize what a pre-launch really is and what marketing really is; especially now as marketing is just weeks down the road.

There have been several experts that focused on sales numbers when talking about Afrezza lately. However, in pre-launch, sales isn’t the top priority. Instead, in the pre-launch phase, Sanofi hoped to learn more about the overall sentiment revolving around the drug. The company has talked to endocrinologists in an attempt to educate them on the benefits of Afrezza. They’ve also taken the time to speak to physicians at the American Diabetes Association to provide even more education on the drug. Now that physicians know about it, it’s almost time to move to the Direct-to-Consumer campaign; which will be all about sales. This is a big step that MNKD and SNY investors have been waiting for as the main focus, unlike the pre-launch, will be getting Afrezza sold!

Why I Think MannKind’s Afrezza Will Be Incredibly Profitable

I’ve talked about this a bit in the past. The bottom line is that I’m a huge fan of Afrezza. The inhaled insulin takes the need of needles away from those who are used to injecting their insulin. This is a major step and will most likely be incredibly appealing to the diabetic community. Although Sanofi hasn’t shown much through the pre-launch, it’s also important to remember that the company specializes in sales; and if the past is any indication, they will likely turn Afrezza into an incredibly profitable proposition.

MNKD Outside Of Afrezza

While I’m expecting that Afrezza sales will pick up and MannKind stock will see a nice spike as a result, it’s important to remember that MannKind is going far further than Afrezza. The technology used to turn insulin into an inhaled product, technosphere, is being tested in other indications at the moment. That means that down the road, we’re likely to see MannKind come out with more and more inhaled medications that were once only available through injections. So, while I do believe Afrezza will be incredibly profitable, we can’t discount the profitability in the MNKD proprietary technosphere technology. All in all, Afrezza is likely to drive sales; from there, technosphere is likely to open the door to several more opportunities. So, I’m expecting big things from MNKD.

What Do You Think?

Are you excited about Sanofi’s direct to consumer campaign? What are you expecting to see from MNKD and SNY moving forward? Let us know in the comments below!

Image Credit

Leave a Comment